Parkinson disease affects approximately 10 million people worldwide and is the fastest-growing neurological disorder by prevalence. Dopaminergic therapy, levodopa, dopamine agonists, and MAO-B inhibitors, remains the mainstay of symptomatic management, while deep brain stimulation is established for motor fluctuations. Disease-modifying strategies targeting alpha-synuclein aggregation, neuroinflammation, and GBA1 mutations represent the most active therapeutic research areas.
Loading articles...
